Clinical trials: Human Papillomavirus Vaccines
Cervical Cancer, Genital Warts
Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)
The primary purpose of the study is to test the safety of HPV Vaccine in Women
- Trial name
- FUTURE (NCT00517309)
- Testing
- V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years
- Volunteers
- 1,877 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Cervical Cancer, HPV-Related Carcinoma
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
- Conditions
- Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma
- Trial name
- NCT06157151
- Testing
- PRGN-2009 plus Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Precigen, Inc
Condylomata Acuminata
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase Ⅱ clinical study was designed to evaluate the immunogenicity and safety of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged 18-55 years…
- Trial name
- NCT02710851
- Testing
- low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
HPV Infection, HPV-Related Carcinoma
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, Genital Wart, HPV-Related Intraepithelial Neoplasia
- Trial name
- NCT06454175
- Testing
- 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female…
- Trial name
- NCT06207175
- Testing
- Nonavalent HPV study vaccine, GARDASIL® 9
- Where
- Indonesia
- Volunteers
- 1,260 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of…
- Trial name
- NCT00534638
- Testing
- Cervarix, Engerix-B
- Where
- 6 sites in Finland
- Volunteers
- 34,412 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Vaccines
HPV Vaccine Confident Families
The objectives of the study are to pilot test a tailored intervention among Black families with adolescents. The hypotheses are that the study protocol will be feasible and messages tailored to parents' needs will increase…
- Trial name
- NCT06002282
- Testing
- Tailored messages, Standard messages
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Infections, Papillomavirus
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e.
- Trial name
- NCT01290393
- Testing
- Data collection
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus, HPV
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Worldwide cervical cancer remains a major cause mortality among women. It is estimated that each year over 490,000 women are diagnosed with cervical cancer and more than 270,000 die from the disease.
- Conditions
- Human Papilloma Virus, HPV, Post Partum
- Trial name
- HPV Acceptance (NCT00730704)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Cervical Cancer
Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making
Preventing cervical cancer is a public health concern. Since 2006 a quadrivalent vaccine for young women nine to twenty six years of age has been available to protect against the human papillomavirus (HPV) and to prevent some…
- Trial name
- NCT00807898
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Human Papillomavirus (HPV) Vaccine
Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule
The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions…
- Trial name
- HPV-022 PRI (NCT00572000)
- Testing
- HPV-16/18 L1 VLP AS04 vaccine
- Where
- Vietnam
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- National Institute for Control of Vaccine and Biologicals
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV), Papillomavirus Vaccines
The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions
The purpose of this study is to examine the impact of a structured educational program based on the Transtheoretical Model (TTM) on HPV knowledge, health beliefs, and vaccination behavioral intentions among first-year nursing…
- Conditions
- Human Papillomavirus (HPV), Papillomavirus Vaccines, Health Knowledge, Attitudes, Practice, Students, Nursing
- Trial name
- NCT07248904
- Testing
- TTM-Based Educational Program
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Cukurova University
Infections, Papillomavirus
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00345878
- Testing
- HPV-16/18 L1 VLP AS04 (Cervarix TM)
- Where
- 2 sites in Malaysia
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Squamous Papilloma of the Larynx
Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis
Vaccines against human papillomaviruses are now commercially available. One of the commercial vaccine contains antigens of both LR HPV types which cause virtually all cases of RRP.
- Trial name
- NCT01375868
- Testing
- Silgard
- Where
- Czechia
- Volunteers
- 51 people
- Sponsor
- Ruth Tachezy, PhD.
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adult Solid Tumor
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune…
- Trial name
- NCT04084951
- Testing
- SQZ-PBMC-HPV, Atezolizumab, Ipilimumab
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- SQZ Biotechnologies
Human Papillomavirus Infection, HPV Vaccines
The Role of Cyberchondria Severity in the Relationship Between HPV Awareness and Vaccination Attitudes in Adult Women
Human papillomavirus (HPV) is a prevalent sexually transmitted infection linked to nearly all cases (99%) of cervical cancer. Prophylactic HPV vaccination is effective in preventing these cancers, complemented by HPV screening…
- Conditions
- Human Papillomavirus Infection, HPV Vaccines, Cyberchondria, Awareness
- Trial name
- NCT06800456
- Where
- Turkey (Türkiye)
- Volunteers
- 337 people
- Sponsor
- Acibadem University